Aurobindo Pharma (Aurobindo Pharma) Total Current Assets : $2,915.59 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Aurobindo Pharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Aurobindo Pharma's total current assets for the quarter that ended in Mar. 2024 was $2,915.59 Mil.

Aurobindo Pharma Total Current Assets Historical Data

The historical data trend for Aurobindo Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Total Current Assets Chart

Aurobindo Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Current Assets

Get a 7-Day Free Trial

2,201.60

2,722.28

2,378.63

2,619.01

2,915.59

Aurobindo Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															2,619.01	-	2,835.58	-	2,915.59

Aurobindo Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Aurobindo Pharma's Total Current Assets for the fiscal year that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	794.011	+	580.181	+	1181.41	+	359.987
	=	2,915.59

Aurobindo Pharma's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	794.011	+	580.181	+	1181.41	+	359.987
	=	2,915.59

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Aurobindo Pharma (GREY:ARBQY) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Aurobindo Pharma's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	794.011	-	1833.348	+	0.75 * 580.181	+	0.5 * 1181.41
=	-13.50

Aurobindo Pharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma (Aurobindo Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (GREY:ARBQY) » Definitions » Total Current Assets

Traded in Other Exchanges

AUROPHARMA:India 524804:India

Address

Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032

Website

https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (Aurobindo Pharma) Headlines

From GuruFocus

Aurobindo Pharma Wins Company of the Year and Acquisition of the Year Awards at the Global Generics & Biosimilars Awards 2019

By PRNewswire PRNewswire • 11-21-2019